PIONEERING PRECISION IN
|
|
|
|
At Photonic Pharma LLC, we focus on the early phase of drug development - Lead Discovery - using a game-changing technology platform that combines breakthroughs in fluorescent biosensor engineering and fluorescence lifetime detection in living cells. Thus we achieve a dramatic 30-fold increase in the precision of high-throughput screening of small-molecule libraries, with the potential to transform the productivity of pharmaceutical development.
We partner with industrial and academic collaborators, applying our proprietary advancements in structure-based drug-screening technology, to discover novel small-molecule effectors of therapeutically important protein targets. We have assembled a robust and highly integrated network of techniques, concepts, facilities and collaborators to address a wide range of therapeutic goals. |
PHOTONIC PHARMA NEWS:
January 15, 2021
Photonic Pharma LLC is pleased to announce that it was awarded its second SBIR Phase I grant from the National Institute on Aging at the National Institutes of Health related to new therapeutic avenues for treatment of Alzheimer's disease.
January 15, 2021
Photonic Pharma LLC is pleased to announce that it was awarded its second SBIR Phase I grant from the National Institute on Aging at the National Institutes of Health related to new therapeutic avenues for treatment of Alzheimer's disease.
For full story and other news, please visit our News page.